Cargando…

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence

OBJECTIVE: Circulating tumor DNA (ctDNA) offers a minimally-invasive alternative to study genomic changes in recurrent malignancies. With a high recurrence rate, the overall survival in high-grade serous ovarian carcinoma (HGSC) has remained low. Our objectives were to determine whether ctDNA from p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchi, Giovanni, Rajavuori, Anna, Nguyen, Mai T.N., Huhtinen, Kaisa, Oksa, Sinikka, Hietanen, Sakari, Hautaniemi, Sampsa, Hynninen, Johanna, Oikkonen, Jaana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641709/ https://www.ncbi.nlm.nih.gov/pubmed/37924564 http://dx.doi.org/10.1016/j.tranon.2023.101814

Ejemplares similares

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer
por: Oikkonen, Jaana, et al.
Publicado: (2019)

QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability
por: Jamalzadeh, Sanaz, et al.
Publicado: (2022)

Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis
por: Skorda, Aikaterini, et al.
Publicado: (2023)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
por: Zhang, Kaiyang, et al.
Publicado: (2022)

Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer
por: He, Liye, et al.
Publicado: (2021)

Author Correction: Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2020)

Virtual clinical trials identify effective combination therapies in ovarian cancer
por: Kozłowska, Emilia, et al.
Publicado: (2019)

FUNGI: FUsioN Gene Integration toolset
por: Cervera, Alejandra, et al.
Publicado: (2021)

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
por: Salminen, Liina, et al.
Publicado: (2021)

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer
por: Perez-Villatoro, Fernando, et al.
Publicado: (2022)

PRISM: recovering cell-type-specific expression profiles from individual composite RNA-seq samples
por: Häkkinen, Antti, et al.
Publicado: (2021)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
por: Roering, Pia, et al.
Publicado: (2022)

A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids
por: Senkowski, Wojciech, et al.
Publicado: (2023)

Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study
por: Laasik, Maren, et al.
Publicado: (2019)

qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets
por: Häkkinen, Antti, et al.
Publicado: (2020)

Agile workflow for interactive analysis of mass cytometry data
por: Casado, Julia, et al.
Publicado: (2020)

Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
por: Jukonen, Joonas, et al.
Publicado: (2021)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
por: Fitzgerald, Sandra, et al.
Publicado: (2023)

Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance
por: Pietilä, Elina A., et al.
Publicado: (2021)

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
por: Keller, Laura, et al.
Publicado: (2020)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer
por: Carroll, Molly J., et al.
Publicado: (2022)

The feasibility of [(18)F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study
por: Laasik, Maren, et al.
Publicado: (2020)

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
por: Lyu, Mengyuan, et al.
Publicado: (2019)

Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA
por: Liu, Zhichao, et al.
Publicado: (2020)

Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer
por: Zhu, Jie Wei, et al.
Publicado: (2023)

H&E image analysis pipeline for quantifying morphological features
por: Ariotta, Valeria, et al.
Publicado: (2023)

Diagnostic efficiency of whole-body (18)F-FDG PET/MRI, MRI alone, and SUV and ADC values in staging of primary uterine cervical cancer
por: Steiner, Aida, et al.
Publicado: (2021)

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay
por: Lyu, Nana, et al.
Publicado: (2020)

The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
por: Sobczuk, Paweł, et al.
Publicado: (2022)

Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei
por: Saarinen, Lilli, et al.
Publicado: (2017)

Tumor Heterogeneity and Drug Resistance Mutations Using ctDNA in Metastatic EGFR Mutation-Positive Lung Adenocarcinoma: A Case Report
por: Sun, Jinghua, et al.
Publicado: (2022)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
por: Xie, Jianjiang, et al.
Publicado: (2023)

Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2023)

High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third‐generation TKI outcomes
por: Li, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ldh40l5lkbvtkl0oa46v1590s